Ovid Therapeutics appoints Charles Carter as CFO, replacing Jeffrey Rona

Ovid Therapeutics Inc.

CFO Jeffrey Rona departed July 6, 2026; no disagreement with company on accounting or financial reporting.
Charles Carter appointed CFO, SVP of Finance since Oct 2024; previously CFO at CERo Therapeutics and iCAD.
Carter receives $460k base salary, 35% target bonus, 50,000 RSUs vesting over 2 years, plus $75k bonus opportunity.
Rona receives 12 months base salary severance, prorated 2026 bonus, COBRA for 12 months, and consulting role through Dec 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.